FLRT2 is involved in the development of ovarian and uterine carcinogenesis, and FLRT2 has been reported to be a tumor suppressor in breast and prostate cancer (Donninger et al., 2004; Santin et al., 2005; Wu et al., 2016; Bae et al., 2017). The gene discussed is FLRT2; the disease is neoplasm.